Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

17 pages and 166 references. Type AML into ASCO 2015 and that is what you get.

How will K fit in? Presumably the bologna trial is for consolidation therapy for AML, with and without the standard, cytarabine. Standard treatment for AML now is cytarabine and daunarubicin for induction and then cytarabine in high doses for consolidation or maintenance. Can K improve on this consolidation cycle of treatment?

Much also written on treating older AML patients or those with other illnesses,who cannot tolerate the standard approach, and are given less toxic options. If K works in AML patients it is easy to foresee a role in this population too, since it is so well tolerated thus far

So much going on though, including CAR T cell approaches, the new bandwagon as many of you already know. This immune approach appears revolutionary. Could K be given at the same time as CAR T ?

Fingers crossed for efficacy.